Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences.[1]
Industry | Biotechnology |
---|---|
Founded | July 1982 |
Founder | David M. Goldenberg |
Defunct | October 23, 2020 |
Headquarters | Morris Plains, New Jersey |
Parent | Gilead Sciences |
Website | www |
Immunomedics was founded in July 1982 by David M. Goldenberg.[2]
Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019.[3] At that time, Dr. Behzad Aghazadeh was named Executive Chairman.[4]
In October 2020, Gilead Sciences acquired the company.[1] In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains. [5]